MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) ...

Performance evaluation of a reflex blood-based methylated ctDNA multi-cancer early detection test in individuals with obesity. A phase 1 study of intracerebroventricular (ICV) delivery of bivalent ...

Nationwide access enabled through Quest Diagnostics' 7,000 patient access sites The Cancerguard test will be delivered through Exact Sciences’ expansive commercial and operational infrastructure, ...

A four-biomarker blood panel of aminopeptidase N (ANPEP), polymeric immunoglobulin receptor (PIGR), CA19-9, and thrombospondin-2 (THBS2) enhanced the detection of pancreatic ductal adenocarcinoma ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Hilary Brueck Every time Hilary publishes a story, you’ll get an alert straight to your inbox!

Angus is STAT’s cancer reporter. Marissa, when not working as an intern, studies extracellular vesicles in the brain in her Ph.D. research. Angus Chen covers all issues broadly related to cancer ...

Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available as ...

Cancer affects millions of people around the world every year. Oftentimes, the signs and symptoms of cancer present themselves once the disease has advanced into its later stages, leaving many wishing ...